- Home
- TBPH vs ASPI Comparison
TBPH vs ASPI Comparison
Compare TBPH & ASPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- ASPI
- Stock Information
- Founded
- TBPH 2013
- ASPI 2021
- Country
- TBPH United States
- ASPI United States
- Employees
- TBPH N/A
- ASPI N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- ASPI Major Chemicals
- Sector
- TBPH Health Care
- ASPI Industrials
- Exchange
- TBPH Nasdaq
- ASPI Nasdaq
- Market Cap
- TBPH 464.5M
- ASPI 470.6M
- IPO Year
- TBPH N/A
- ASPI 2022
- Fundamental
- Price
- TBPH $10.92
- ASPI $7.02
- Analyst Decision
- TBPH Strong Buy
- ASPI Strong Buy
- Analyst Count
- TBPH 5
- ASPI 2
- Target Price
- TBPH $16.60
- ASPI $7.75
- AVG Volume (30 Days)
- TBPH 366.7K
- ASPI 4.0M
- Earning Date
- TBPH 08-04-2025
- ASPI 08-18-2025
- Dividend Yield
- TBPH N/A
- ASPI N/A
- EPS Growth
- TBPH N/A
- ASPI N/A
- EPS
- TBPH N/A
- ASPI N/A
- Revenue
- TBPH $65,266,000.00
- ASPI $4,405,477.00
- Revenue This Year
- TBPH $43.18
- ASPI $512.64
- Revenue Next Year
- TBPH N/A
- ASPI $181.15
- P/E Ratio
- TBPH N/A
- ASPI N/A
- Revenue Growth
- TBPH 6.11
- ASPI 245.97
- 52 Week Low
- TBPH $7.44
- ASPI $1.86
- 52 Week High
- TBPH $11.82
- ASPI $10.08
- Technical
- Relative Strength Index (RSI)
- TBPH 60.52
- ASPI 45.85
- Support Level
- TBPH $10.46
- ASPI $6.84
- Resistance Level
- TBPH $11.44
- ASPI $8.15
- Average True Range (ATR)
- TBPH 0.27
- ASPI 0.61
- MACD
- TBPH -0.01
- ASPI -0.17
- Stochastic Oscillator
- TBPH 56.65
- ASPI 14.81
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a pre-commercial stage advanced materials company dedicated to the development of technology and processes that, if successful, will allow for the production of isotopes that may be used in several industries. The company utilizes technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses.